Alexei Zelenev, PhD
DownloadHi-Res Photo
Cards
Contact Info
About
Titles
Associate Research Scientist in Medicine (AIDS)
Biography
Alexei Zelenev is a a research scientist and a faculty member at the Yale School of Medicine (AIDS program). His research has focused on the interplay of infectious diseases, substance abuse disorder and social networks. He obtained his BA from University of Chicago and his PhD from Yale University. He has advanced knowledge of survey design and implementation, applied statistics and simulation based methods. His research has appeared in such peer-reviewed journals as Lancet Infectious Diseases, Lancet HIV, International Journal of Drug Policy, Drug and Alcohol Dependence, AIDS and Behavior, among others. Dr. Zelenev served as an advisor to the Health Emergencies Program at the WHO. His infectious disease modeling work has been used to guide health policy in Ukraine and Kazakhstan during the height of the Covid pandemic.
Appointments
AIDS
Associate Research ScientistPrimary
Other Departments & Organizations
Education & Training
- PhD
- Yale University (2011)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Alexei Zelenev's published research.
Publications Timeline
A big-picture view of Alexei Zelenev's research output by year.
Frederick Lewis Altice, MD, MA
Jianghong Li, MD
Lynn Madden, PhD, MPA
Mayur M. Desai, PhD, MPH, FACE
6Publications
200Citations
Publications
2024
The impact of emergency guidance to the COVID‐19 pandemic on treatment entry, retention and mortality among patients on methadone in Ukraine
Ivasiy R, Madden L, Meteliuk A, Machavariani E, Ahmad B, Zelenev A, Desai M, Bromberg D, Polonsky M, de Leon S, Farnum S, Islam Z, Altice F. The impact of emergency guidance to the COVID‐19 pandemic on treatment entry, retention and mortality among patients on methadone in Ukraine. Addiction 2024 PMID: 38807448, DOI: 10.1111/add.16565.Peer-Reviewed Original ResearchAltmetricConceptsOpioid agonist therapyTake-home dosesCOVID-19 guidancePre-COVID cohortAgonist therapyOptimal doseTreatment retentionEmergency guidanceEffective HIV prevention strategiesAdult HIV prevalenceHIV prevention strategiesMinistry of HealthImprove treatment retentionMethadone dosePatient survivalTime-dependent predictorsProspective cohortHIV prevalencePredictors of treatment retentionGovernmental clinicsPrimary outcomeHazard ratioPatient enrollmentPatientsMethadone patients
2023
Social networks, secondary syringe exchange, and opioid agonist therapy retention among people who inject drugs in Hartford, CT
Zelenev A, Michael L, Li J, Altice F. Social networks, secondary syringe exchange, and opioid agonist therapy retention among people who inject drugs in Hartford, CT. International Journal Of Drug Policy 2023, 123: 104250. PMID: 38088004, DOI: 10.1016/j.drugpo.2023.104250.Peer-Reviewed Original Research
2017
Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study
Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL. Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study. The Lancet Infectious Diseases 2017, 18: 215-224. PMID: 29153265, PMCID: PMC5860640, DOI: 10.1016/s1473-3099(17)30676-x.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntiviral AgentsChemopreventionCitiesComputer SimulationDisease Transmission, InfectiousFemaleHepatitis CHumansMaleMiddle AgedModels, StatisticalPrevalenceSubstance Abuse, IntravenousSurveys and QuestionnairesTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsBaseline HCV prevalenceHepatitis C virusHCV prevalenceInjection partnersPrevention strategiesTreatment coverageTransmission of HCVHepatitis C virus (HCV) treatmentHCV elimination strategySuccessful HCV treatmentC virus treatmentInjection drug usersHCV treatment coverageAdditional network memberHCV treatmentActing antiviralsC virusChronic infectionVirus treatmentDrug usersPrevalenceDrug abuseDrugsNational InstitutePreventionOverlooked Threats to Respondent Driven Sampling Estimators: Peer Recruitment Reality, Degree Measures, and Random Selection Assumption
Li J, Valente TW, Shin HS, Weeks M, Zelenev A, Moothi G, Mosher H, Heimer R, Robles E, Palmer G, Obidoa C. Overlooked Threats to Respondent Driven Sampling Estimators: Peer Recruitment Reality, Degree Measures, and Random Selection Assumption. AIDS And Behavior 2017, 22: 2340-2359. PMID: 28660381, PMCID: PMC5745307, DOI: 10.1007/s10461-017-1827-1.Peer-Reviewed Original ResearchCitationsAltmetric
2016
The complex interplay of social networks, geography and HIV risk among Malaysian Drug Injectors: Results from respondent-driven sampling
Zelenev A, Long E, Bazazi AR, Kamarulzaman A, Altice FL. The complex interplay of social networks, geography and HIV risk among Malaysian Drug Injectors: Results from respondent-driven sampling. International Journal Of Drug Policy 2016, 37: 98-106. PMID: 27639995, PMCID: PMC5102779, DOI: 10.1016/j.drugpo.2016.08.008.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHIV statusHIV transmissionClean needlesRecent injection partnersHigh-risk populationRisk reduction interventionsTargeting of interventionsPublic health surveillanceRespondent-driven samplingInjection partnersHIV preventionHIV riskTreatment coverageDrug injectorsHIVPrevention strategiesPWIDHealth surveillanceGreater Kuala LumpurKuala LumpurInterventionSurveillanceImportant mechanismStatus
2014
Strategies for Hepatitis C Testing and Linkage to Care for Vulnerable Populations: Point-of-Care and Standard HCV Testing in a Mobile Medical Clinic
Morano JP, Zelenev A, Lombard A, Marcus R, Gibson BA, Altice FL. Strategies for Hepatitis C Testing and Linkage to Care for Vulnerable Populations: Point-of-Care and Standard HCV Testing in a Mobile Medical Clinic. Journal Of Community Health 2014, 39: 922-934. PMID: 25135842, PMCID: PMC8317466, DOI: 10.1007/s10900-014-9932-9.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHCV testing strategyMobile medical clinicHCV testingHCV careHCV treatmentPatient preferencesPOC testingPrior injection drug useMedical clinicsHepatitis C testingReactive test resultsInjection drug useRoutine health assessmentsPrior STI diagnosisTesting strategiesHCV prevalenceStandard phlebotomySTI diagnosisTherapeutic advancesSpecialty clinicSerological testingWhite raceC testingDrug useHCV
Links & Media
News
- January 01, 2020
Yale study urges life-saving drug treatment to combat Ukraine’s HIV epidemic
- November 28, 2017
Hepatitis C ‘treatment as prevention’ strategy examined in new study
- January 20, 2014
HIV-infected women experience worse treatment outcomes after release from jail
- June 04, 2013
An urban challenge: diagnosing and treating latent tuberculosis infection